GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Boric Acid and Quercetin Found to Reduce Neurotoxicity Caused by Paraquat Through Antioxidant Properties

by GOAI
Share To

Recent research has examined the protective effects of boric acid and quercetin against neurotoxicity caused by paraquat, a widely used herbicide known for its harmful impact on the nervous system. The study, conducted by Güner and Tekin, focused on the antioxidant properties of these natural compounds and their ability to mitigate damage associated with paraquat exposure.

The findings highlight that both boric acid and quercetin possess significant antioxidant capabilities, which may play a role in reducing oxidative stress induced by paraquat. Paraquat is recognized for its potential to cause cellular damage through the generation of reactive oxygen species, leading to neurodegeneration. The study investigated how these compounds interact with paraquat’s toxic mechanisms and found evidence suggesting they can counteract its harmful effects. Researchers analyzed various biochemical markers related to oxidative stress and neurotoxicity during the study to assess the efficacy of boric acid and quercetin in protecting neural cells from damage.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top